Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/1999

01-12-1999 | Paper Report

Visibility of cancer on earlier mammograms in the Finnish breast screening programme

Author: Jenny McCann

Published in: Breast Cancer Research | Issue 1/1999

Login to get access

Excerpt

High sensitivity and specificity are essential qualities in a good screening programme. The false negative rate is determined by the experience and skill of the radiologist as well as by breast density and tumour characteristics. Film quality and breast positioning are also important. Review of earlier mammograms of screen-detected and interval cancers allows estimation of the number whose diagnosis could have been advanced to the previous screening test. Radiological and clinical differences may be compared between those that are visible on previous films and those that are not. …
Literature
1.
Saarenmaa I, Salminen T, Geiger U, Holli K, Isola J, Karkkainen A, Pakkanen J, Piironen A, Salo A, Hakama M: The visibility of cancer on earlier mammograms in a population-based screening programme. Eur J Cancer. 1999, 35: 1118-1122.CrossRefPubMed
Metadata
Title
Visibility of cancer on earlier mammograms in the Finnish breast screening programme
Author
Jenny McCann
Publication date
01-12-1999
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/1999
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-1999-66608

Other articles of this Issue 1/1999

Breast Cancer Research 1/1999 Go to the issue

Paper Report

High dose chemotherapy in inflammatory breast cancer

Paper Report

Use of cDNA microarrays in breast cancer

Commentary

Killing the umpire: cooperative defects in mitotic checkpoint and BRCA2 genes on the road to transformation

Paper Report

Liposome-plasmid complexes encoding angiostatin and endostatin inhibit breast cancer in nude mice

Paper Report

Epstein-Barr virus in breast cancers

Paper Report

Idoxifene antagonises E2-dependent breast cancer xenograft growth through apoptosis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits